File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Repeat transrectal ultrasound‐guided prostate biopsy for elevated PSA with prior negative biopsy, how many biopsies is enough?

TitleRepeat transrectal ultrasound‐guided prostate biopsy for elevated PSA with prior negative biopsy, how many biopsies is enough?
Authors
Issue Date2019
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/
Citation
The 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 14 How to Cite?
AbstractObjective: This study aims 1) to identify the predictive factors for prostate cancer detection in repeat TRUS biopsy and 2) to illustrate the incidence of prostate cancer in repeat biopsies. Patients and Methods: A retrospective analysis was carried out in patients who underwent TRUS biopsy in our hospital between January 2000 to December 2013. Patient demographics, digital rectal examination finding, PSA level, prostate volume, number of biopsies and biopsy results were analysed. Results: 682 patients underwent repeat TRUS biopsy for elevated PSA with prior negative biopsy. Multivariate analysis showed that PSA density (OR 5.107, Cl 1.31–19.9, p = 0.019) and abnormal DRE (OR 2.36, Cl 1.19–4.70, p = 0.014) were independent factors associated with malignancy in second biopsy. The cut off PSA density defined by the ROC curve is >= 0.176 ng/mL with sensitivity of 75.7% and specificity of 42.7%. In addition, the detection rate of clinically significant prostate cancer (Gleason score > 6) decreased by the fourth repeat biopsy (19.9%, 3.23%, 4.25% and 0%, from first to fourth biopsy). Conclusion: When patients are under PSA observation following a non‐targeted TRUS biopsy, PSA density and DRE findings should be used to guide decisions on whether the patients require a repeat biopsy.
DescriptionPoster presentation
Persistent Identifierhttp://hdl.handle.net/10722/266479
ISSN
2020 Impact Factor: 5.588
2015 SCImago Journal Rankings: 2.009

 

DC FieldValueLanguage
dc.contributor.authorWong, TTF-
dc.contributor.authorTsang, CF-
dc.contributor.authorLam, PW-
dc.contributor.authorWong, KWC-
dc.contributor.authorLai, TCT-
dc.contributor.authorHo, SHB-
dc.contributor.authorNg, ATL-
dc.contributor.authorMa, WK-
dc.contributor.authorTsu, HLJ-
dc.date.accessioned2019-01-18T08:20:28Z-
dc.date.available2019-01-18T08:20:28Z-
dc.date.issued2019-
dc.identifier.citationThe 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 14-
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/266479-
dc.descriptionPoster presentation-
dc.description.abstractObjective: This study aims 1) to identify the predictive factors for prostate cancer detection in repeat TRUS biopsy and 2) to illustrate the incidence of prostate cancer in repeat biopsies. Patients and Methods: A retrospective analysis was carried out in patients who underwent TRUS biopsy in our hospital between January 2000 to December 2013. Patient demographics, digital rectal examination finding, PSA level, prostate volume, number of biopsies and biopsy results were analysed. Results: 682 patients underwent repeat TRUS biopsy for elevated PSA with prior negative biopsy. Multivariate analysis showed that PSA density (OR 5.107, Cl 1.31–19.9, p = 0.019) and abnormal DRE (OR 2.36, Cl 1.19–4.70, p = 0.014) were independent factors associated with malignancy in second biopsy. The cut off PSA density defined by the ROC curve is >= 0.176 ng/mL with sensitivity of 75.7% and specificity of 42.7%. In addition, the detection rate of clinically significant prostate cancer (Gleason score > 6) decreased by the fourth repeat biopsy (19.9%, 3.23%, 4.25% and 0%, from first to fourth biopsy). Conclusion: When patients are under PSA observation following a non‐targeted TRUS biopsy, PSA density and DRE findings should be used to guide decisions on whether the patients require a repeat biopsy.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/-
dc.relation.ispartofBJU International-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.titleRepeat transrectal ultrasound‐guided prostate biopsy for elevated PSA with prior negative biopsy, how many biopsies is enough?-
dc.typeConference_Paper-
dc.identifier.emailLam, PW: lamwayne@hku.hk-
dc.identifier.emailWong, KWC: kwwongab@HKUCC-COM.hku.hk-
dc.identifier.emailHo, SHB: hobrian@hku.hk-
dc.identifier.emailNg, ATL: ada5022@hku.hk-
dc.identifier.emailMa, WK: mwk054@hku.hk-
dc.identifier.emailTsu, HLJ: jamestsu@hku.hk-
dc.identifier.authorityLam, PW=rp02305-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bju.14677-
dc.identifier.scopuseid_2-s2.0-85062970946-
dc.identifier.hkuros296736-
dc.identifier.volume123-
dc.identifier.issueS1-
dc.identifier.spage14-
dc.identifier.epage14-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1464-4096-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats